Home / Business and Economy / GLP-1 Drugs Spark New Boom in Aesthetics Market
GLP-1 Drugs Spark New Boom in Aesthetics Market
4 May
Summary
- Aesthetic firms see demand rise from GLP-1 drug users experiencing skin laxity.
- Weight loss drugs like Wegovy and Zepbound are more affordable for consumers.
- Cosmetic procedures such as breast augmentation and facial fillers are expected to grow.
The aesthetics industry is anticipating a new wave of demand fueled by the growing number of patients using GLP-1 weight loss drugs. These medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, are now available to many U.S. patients for under $500 a month. This increased accessibility is leading to significant weight loss, often resulting in loose skin and facial volume loss, creating opportunities for aesthetic treatments.
Companies like Apyx Medical and InMode are preparing for increased demand for skin-tightening procedures. Establishment Labs, a manufacturer of breast implants, and Evolus, a maker of facial fillers, are also positioning for growth. Analysts predict that the "Ozempic face" phenomenon, characterized by facial sagging from rapid weight loss, will drive demand for injectables. This shift is seen as structural, indicating sustained growth in the aesthetics sector.
